Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-05 | Direct | 5,619 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 5,619 · Balance 5,619 F1: 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 8,188 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 8,188 · Balance 8,188 F2: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.
F2: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 169,712 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 66,931 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 33,778 · Balance 0 F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 3,868 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Disposition to issuer · Disposed 149,470 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.66 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.64 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-01 · Disposition to issuer · Disposed 240,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-01 · Disposition to issuer · Disposed 120,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.00 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-01 · Disposition to issuer · Disposed 78,960 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 66,931 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)
F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 16, 2026 22:19 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 8,188 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001786966-26-000003 · primarydocument.xml · derivative · entry 2 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,188 Underlying: Common Stock · 8,188 shares Expires 2036-06-05 F2 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:19 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 5,619 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001786966-26-000003 · primarydocument.xml · derivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,619 Underlying: Common Stock · 5,619 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,690 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 15 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,690 shares Expires 2028-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,236 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 14 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,236 shares Expires 2029-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,605 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 13 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,605 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,477 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 12 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,477 shares Expires 2031-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,463 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 11 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,463 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 66,477 | $29.44 | $1,957,082.88 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 10 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,820 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 10,463 | $29.44 | $308,030.72 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 9 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,297 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,605 | $29.44 | $223,891.20 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 8 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 17,236 | $29.44 | $507,427.84 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 7 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 13,690 | $29.44 | $403,033.60 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 6 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,601 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,605 | $0.71 | $5,399.55 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 5 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 66,477 | $1.93 | $128,300.61 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 4 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,463 | $1.93 | $20,193.59 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,236 | $0.64 | $11,031.04 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 13,690 | $0.39 | $5,339.10 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,960 | Not disclosed Strike: $43.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 8 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,960 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 120,000 | Not disclosed Strike: $38.40 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 7 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 240,000 | Not disclosed Strike: $27.64 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 6 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $33.66 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 5 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 149,470 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 4 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 149,470 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,868 | Not disclosed Strike: $1.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,868 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerPerformance Share Units · Derivative | 33,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · derivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,778 shares Expires not disclosed F5 · derivative.exercise_price: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 16:26 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerCommon Stock | 169,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065322 · tm2519678-15_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Includes 66,931 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 23:37 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.68 | $0.00 |
DisclosureSEC source: 0001562180-25-004960 · primarydocument.xml · derivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 400 | $56.20 | $22,481.00 |
DisclosureSEC source: 0001104659-25-021008 · tm258294-2_4seq1.xml · nonDerivative · entry 4 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,712 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.90 to $56.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 3,598 | $55.12 | $198,330.76 |
DisclosureSEC source: 0001104659-25-021008 · tm258294-2_4seq1.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,112 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.74 to $55.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 12,078 | $54.26 | $655,330.54 |
DisclosureSEC source: 0001104659-25-021008 · tm258294-2_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,710 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.73 to $54.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 3,924 | $53.12 | $208,449.94 |
DisclosureSEC source: 0001104659-25-021008 · tm258294-2_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,788 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.725 to $53.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 19:55 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 30,000 | $53.13 | $1,593,795.00 |
DisclosureSEC source: 0001104659-25-012359 · tm256428-1_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,712 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 78,960 | $0.00 Strike: $43.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003462 · tm253183-3_4seq1.xml · derivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,960 Underlying: Common Stock · 78,960 shares Expires 2035-01-10 F2 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 10, 2025, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 27,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003462 · tm253183-3_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,712 F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 19:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 4,416 | $38.86 | $171,605.76 |
DisclosureSEC source: 0001104659-25-001768 · tm252237-2_4seq1.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,689 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 19:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 5,561 | $38.19 | $212,374.59 |
DisclosureSEC source: 0001104659-25-001768 · tm252237-2_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,105 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2025 Filed Jan 7, 2025 19:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 6,934 | $38.19 | $264,809.46 |
DisclosureSEC source: 0001104659-25-001768 · tm252237-2_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,666 F1 · security: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 18:14 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 8,034 | $42.24 | $339,393.92 |
DisclosureSEC source: 0001104659-24-125969 · tm2430055-2_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.555. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 18:14 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 11,966 | $41.78 | $499,941.87 |
DisclosureSEC source: 0001104659-24-125969 · tm2430055-2_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,634 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.09 to $42.085. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 16:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 3,080 | $42.08 | $129,591.00 |
DisclosureSEC source: 0001104659-24-096869 · tm2423359-1_4seq1.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 16:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 4,620 | $41.12 | $189,955.00 |
DisclosureSEC source: 0001104659-24-096869 · tm2423359-1_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,680 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.77 to $41.725. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 16:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 12,300 | $40.11 | $493,408.35 |
DisclosureSEC source: 0001104659-24-096869 · tm2423359-1_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $40.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 23:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 20,594 | $0.00 Strike: $17.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005018 · primarydocument.xml · derivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,594 Underlying: Common Stock · 20,594 shares Expires 2034-06-10 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the 2025 annual meeting of stockholders. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:07 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 385 | $42.04 | $16,184.09 |
DisclosureSEC source: 0001104659-24-068673 · tm2416457-1_4seq1.xml · nonDerivative · entry 4 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.99 to $42.065. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:07 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 3,651 | $41.38 | $151,066.33 |
DisclosureSEC source: 0001104659-24-068673 · tm2416457-1_4seq1.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,985 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.98 to $41.955. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:07 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 4,192 | $40.62 | $170,287.00 |
DisclosureSEC source: 0001104659-24-068673 · tm2416457-1_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,636 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.98 to $40.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:07 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 11,772 | $39.40 | $463,834.46 |
DisclosureSEC source: 0001104659-24-068673 · tm2416457-1_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,828 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 08, 2024 Filed Jan 8, 2024 21:09 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 5,466 | $41.53 | $227,002.98 |
DisclosureSEC source: 0001104659-24-002374 · tm242462-3_4seq1.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,600 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 21:09 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 4,469 | $37.96 | $169,643.24 |
DisclosureSEC source: 0001104659-24-002374 · tm242462-3_4seq1.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,066 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:09 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001104659-24-002374 · tm242462-3_4seq1.xml · derivative · entry 4 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2034-01-03 F3 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:09 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 42,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-002374 · tm242462-3_4seq1.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,535 F1 · security: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.